# A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

> **NCT02944448** · PHASE2 · COMPLETED · sponsor: **Cara Therapeutics, Inc.** · enrollment: 761 (actual)

## Conditions studied

- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Arthritis
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases

## Interventions

- **DRUG:** CR845 tablet 1 mg
- **DRUG:** CR845 tablet 2.5 mg
- **DRUG:** CR845 tablet 5 mg
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT02944448
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-05
- **Final completion:** 2017-06
- **Target enrollment:** 761 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944448, "A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02944448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*